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Abstract 
Introduction: Two thirds of individuals identified as ultra-high risk (UHR) for psychosis do not 
transition to psychosis over the medium to long-term (non-transition; UHR-NT). Nevertheless, 
many of these individuals have persistent attenuated psychotic symptoms (APS). The current study 
examined whether there were differences in baseline grey matter volume (i.e. at initial identification 
as UHR) in UHR-NT individuals whom had APS compared to those without APS (No-APS) at 
medium to long-term follow-up. 
Methods: Participants were help-seeking individuals who were identified as being at UHR for 
psychosis between 2 and 12 years previously (mean=7.5). The sample consisted of 109 participants 
who underwent a Magnetic Resonance Imaging scan at baseline and who had not been observed to 
develop a psychotic disorder over the follow-up period (UHR-NT). Using voxel-based 
morphometry, baseline grey matter volume (GMV) was compared between participants with 
(N=30) and without (N=79) APS at follow-up.  
Results: At baseline, the APS and No-APS groups were clinically indistinguishable. At follow-up, 
the APS group had significantly worse symptoms and impaired functioning. Individuals with APS 
had reduced baseline GMV in frontal, temporal, posterior and cingulate regions compared to those 
without APS at follow-up. Reduced GMV was associated with more severe positive, negative and 
depressive symptoms and lower global functioning in the combined UHR-NT cohort. These 
associations were independent of later APS outcome.    
Discussion: This study found that differences in regional GMV are discernible at an early stage of 
UHR and may be specific to individuals who have APS and psychopathology at follow-up. Our 
findings suggest that lower GMV at baseline may confer neurobiological risk for later APS and/or 
increased psychopathology while the absence of these structural abnormalities might be protective.  
 
Keywords: ultra-high risk, psychosis, attenuated psychotic symptoms, non-transition, imaging, 
grey matter volume  
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1. Introduction 
A large body of research has examined the neuroanatomical characteristics of clinical help-seeking 
samples identified as being at ultra high-risk (UHR) for psychosis. Both cross-sectional and 
longitudinal studies have typically focused on identifying differences between individuals with 
clinical UHR in comparison to healthy controls, as well as individuals categorized either as having 
transitioned (UHR-T) or not transitioned (UHR-NT) to psychosis in order to identify vulnerability 
predictors for transition to psychotic illness. Research employing structural magnetic resonance 
imaging (MRI) has reported subtle but widespread neuroanatomical abnormalities in temporo-
parietal, prefrontal and limbic regions in UHR, with evidence for more pronounced abnormalities in 
UHR-T (for reviews see Bois et al., 2015; Fusar-Poli et al., 2011; Smieskova et al., 2010). 
However, about two-thirds of help-seeking individuals identified as at risk for developing psychosis 
do not transition to frank psychotic disorder over the medium term (Fusar-Poli et al., 2012). This 
suggests that neuroanatomical alterations in UHR may represent markers other than, or in addition 
to, vulnerability to psychosis, such as outcomes related to non-transition or other non-psychotic 
disorders. Despite the large proportion of UHR individuals who do not develop psychosis there is 
little research examining the clinical and biological correlates of this cohort followed over the long-
term.  
 
There is a paucity of imaging studies in UHR that have specifically assessed the morphological 
characteristics of individuals who did not develop psychosis. Of studies that compared UHR-NT 
individuals to controls, increases (Fornito et al., 2008), decreases (Garner et al., 2005; Phillips et al., 
2002) and no change (McIntosh et al., 2011; Takahashi et al., 2009; Ziermans et al., 2012) in brain 
structure have been identified in UHR-NT. Even fewer studies have examined neuroimaging 
indices in relation to clinical outcomes of UHR-NT. To our knowledge, only one brain structural 
study has defined subgroups of UHR-NT according to their long-term clinical outcome; those who 
remained „well‟ (no symptoms) and those who reported one or more psychotic symptoms 
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throughout the follow-up period (McIntosh et al., 2011). Although no differences in brain structure 
(either at baseline or over time) were detected between the two UHR-NT subgroups, this study 
raises the possibility that other outcomes of the UHR-NT group might be associated with discrete 
neurobiological changes. In addition, as this study consisted of relatives who were at risk for 
schizophrenia (genetic at-risk paradigm) it is possible that individuals with an elevated risk for 
psychosis based on clinical or help-seeking factors might show a different neuroanatomical profile 
(see Nenadic et al., 2015). 
 
Recent studies have demonstrated that UHR-NT individuals have a wide range of outcomes with 
respect to symptomatic, functional and non-psychotic disability (Schlosser et al., 2012). At follow-
up, many individuals present with significant non-psychotic mental health problems, poor 
psychosocial functioning and negative symptoms (e.g. Addington et al., 2011; Lin et al., 2011; 
Salokangas et al., 2013). A proportion (23-50%) of UHR-NT individuals also experience attenuated 
psychotic symptoms (APS) (Addington et al., 2011; Haroun et al., 2006; Lemos-Giraldez et al., 
2009; Simon and Umbricht, 2010; Velthorst et al., 2011; Ziermans et al., 2011), which often co-
occur with functional impairment and comorbidity. The presence of APS in UHR-NT individuals 
provides the opportunity to assess the impact of subthreshold intensity or frequency of psychotic 
symptoms on biological indices. This is highly relevant given recent discussions concerning the 
arbitrary nature of the cut-off for psychosis that may not be optimal for measuring associated 
functional and neurobiological changes (see Lin et al., 2012). As the UHR literature has primarily 
examined neurobiological correlates of threshold psychotic symptoms (i.e. symptoms exceeding the 
threshold for frank psychotic disorder), the neurobiological associations of attenuated 
(subthreshold) psychotic symptoms remain unknown.  
 
We have recently examined the course and outcomes of UHR individuals who did not develop a 
psychotic disorder over a period of 2 to 14 years (the PACE 400 sample) (Lin et al., 2015). This 
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work identified that 28% of individuals reported APS at follow-up. The current study aimed to 
assess the brain structural predictors of the APS outcome in this UHR-NT cohort. We sought to 
examine whether there were differences in baseline grey matter volume (GMV) in UHR-NT 
individuals whom had APS compared to those who did not experience such symptoms at follow-up 
(No-APS). Based on structural imaging studies in UHR-T, and given the arbitrary nature of the 
„psychosis threshold‟ (Yung et al., 2010), we predicted that individuals with APS at follow-up 
would have reduced GMV at baseline in prefrontal, temporal and limbic regions compared to UHR-
NT individuals with No-APS.      
 
2. Methods 
2.1 Participants and design 
PACE is a specialist clinic for young people at UHR for psychosis in Melbourne, Australia. Data 
for the current study was taken from a larger sample of 416 UHR individuals, described previously 
(Lin et al., 2015; Nelson et al., 2013). The current study involves only the UHR-NT individuals 
whom had undergone a structural MRI scan at baseline (N=114). Of these participants, 34 presented 
with current APS at follow-up that were at/above the threshold for UHR (but below the threshold 
for transition) and 80 reported no APS (below UHR threshold; No-APS) at follow-up (see Lin et al., 
2015 for full description of APS in the wider PACE sample). The presence of APS was not 
measured in the interim of the baseline and follow-up assessment. Of this dataset, 5 scans were 
excluded; one for having a different voxel size to the rest of the scans and 4 for having poor 
covariance after preprocessing, leaving a total sample of 109 individuals (30 APS, 79 No-APS at 
follow-up) in the current study.  
 
At baseline, participants were aged 15 to 30 years and met UHR criteria, defined by presenting with 
at least one of: 1) attenuated psychotic symptoms, 2) brief limited intermittent psychotic symptoms, 
and/or 3) trait vulnerability for psychotic illness (schizotypal personality disorder or history of 
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psychosis in a first-degree relative) and deterioration in functioning or chronic low functioning (see 
Nelson et al., 2013 for full description of UHR criteria of this cohort). Exclusion criteria for entry to 
PACE are a previous psychotic episode, organic cause for presentation or past anti-psychotic 
exposure equivalent to a haloperidol dose of >15 mg. Participants with and without APS were 
matched for age and gender. The local Research and Ethics Committee approved the study. All 
participants provided written informed consent.  
 
2.3 Clinical measures 
At baseline, psychopathology was measured using the psychotic subscale of the Brief Psychiatric 
Rating Scale (BPRS) (Overall and Gorham, 1962), Scale of Assessment for Negative Symptoms 
(SANS) (Andreasen, 1981) and The Comprehensive Assessment of At-Risk Mental States 
(CAARMS) (Yung et al., 2005). CAARMS positive subscales were disorders of thought content, 
perceptual abnormalities and conceptual disorganisation. Functioning was assessed with the Global 
Assessment of Functioning (GAF) (Endicott et al., 1976) and current IQ with the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R; Wechsler, 1981) or the Wechsler Abbreviated Scale of 
Intelligence (WASI; Wechsler, 1999) following the procedure outlined in Lin et al., (2011). 
Younger participants were assessed using the Wechsler Intelligence Scale for Children (WISC-III; 
Wechsler, 1991) as an alternative to the WAIS-R. At follow-up the CAARMS was used to assess 
the presence of APS. Psychopathology was measured using the BPRS, SANS, Hamilton Anxiety 
Rating Scale (HAM-A) (Hamilton, 1959) and Hamilton Depression Rating Scale (HAM-D) 
(Hamilton, 1960) and functioning with the GAF.  
 
2.4 MRI acquisition 
50.5% of the T1-weighted MRI scans were acquired on a 1.5T GE Signa MR scanner with the 
following parameters: 124 slices of 1.5mm thickness, TR=1.43s, TE=3.3ms, flip angle 30º, matrix 
256x256, FOV 24cm. The remaining 49.5% of MRI scans were acquired on a 3T GE LX Horizon 
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Scanner: 124 slices of 2mm thickness, TR=3.6s, TE=9ms, flip angle 30º, matrix 410x410, FOV 
20cm. The APS and No-APS groups were matched on the proportion undergoing 1.5T versus 3T. 
 
2.5 Voxel-based morphometry 
Whole-brain voxelwise analysis of baseline GMV was conducted using optimized voxel-based 
morphometry (VBM8), as implemented in statistical parametric mapping (SPM8) software 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) running in Matlab R2014b 
http://www.mathworks.com.au/products/matlab/). Briefly, T1 images were normalized to a template 
space and segmented into grey matter, white matter and cerebrospinal fluid. Native-space grey 
matter segments were then spatially aligned to a high-dimensional Diffeomorphic Anatomical 
Registration Through Exponentiated Lie Algebra (DARTEL) template and normalized to MNI 
space. Grey matter voxels were multiplied by the non-linear components only (modulated 
normalized – non-linear only) to provide a measure of the absolute amount of tissue corrected for 
individual brain sizes. Data quality and homogeneity of the images were checked. Images of four 
participants were excluded from the original dataset due to the covariance being more than two 
standard deviations removed from the mean. Prior to statistical analysis, images were smoothed 
with an 8mm full-width-half-maximum Gaussian kernel.    
 
2.6 Statistical analysis 
The General Linear Model (GLM) was performed to test for group differences in baseline GMV at 
each voxel. An independent t-test with age at baseline, sex and field strength of the scanner as 
nuisance factors was defined to test for volumetric differences between the APS and No-APS 
groups. Group differences were corrected for statistical type I error with a cluster-based procedure 
(Friston et al., 1994) using the 3dClustSim tool implemented in AFNI 
(http://afni.nimh.nih.gov/pub/dist/doc/program_help/3dClustSim.html). A voxel-wise threshold was 
set to 0.01 to compromise between sensitivity to spatially extended versus focal and intense 
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differences. Cluster size threshold (i.e. k values) was corrected for non-stationarity (Hayasaka et al., 
2004) with the VBM8 toolbox (http://dbm.neuro.uni-jena.de/467/).  
 
Statistical analyses of demographic and clinical variables were performed using the Statistical 
Package for Social Sciences (SPSS, v21.0). Differences in these variables between groups were 
analysed with independent t-tests or Pearson‟s 2 statistics for continuous and categorical variables, 
respectively. The Mann-Whitney U Test was performed for non-parametric variables. Correlations 
were analysed between the mean GMV extracted from the significant cluster detected in the group 
comparison and clinical variables at follow-up (BPRS, SANS, GAF, HAM-A, HAM-D) using 
Pearson‟s correlation coefficient with bootstrapping (5000 samples) or Spearman‟s correlation 
coefficient for non-parametric variables. Correlations were performed in the whole (combined) 
sample and in each group (APS and No-APS) separately. Correlations between mean GMV and 
clinical variables at baseline, and with change scores (follow-up minus baseline score), were 
explored. P-values <0.05 was considered statistically significant.  
 
3. Results 
3.1 Demographics and clinical characteristics of study sample 
Demographic and clinical characteristics of the APS and No-APS groups are presented in Table 1. 
In this sample, follow-up was conducted between 2 and 12 years after baseline (M=7.5; SD=3.0; 
median=6.9). The APS and No-APS groups were well matched in age at baseline, sex, field 
strength of scanner, time to follow-up and in the UHR membership criteria at intake. At baseline, 
the APS and No-APS groups showed no differences in positive and negative symptoms and 
functioning. However the APS group had a significantly lower IQ than the No-APS group. At 
follow-up, the APS group had significantly higher symptoms (positive, negative, anxiety and 
depression) and lower functioning. Antipsychotic and antidepressant use at baseline (i.e. at time of 
scanning) was documented for 70% of the sample. Of these participants, none reported taking 
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antipsychotics and 10 (13.2%) reported using antidepressants. Antipsychotic and psychiatric 
medication use for the entire follow-up period (i.e. after baseline) was documented for 90% of the 
sample. Of these participants, 5 (5.1%) reported using antipsychotic medication and 46 (47%) 
reported using any psychiatric medication “some or all of the time” in the follow-up period. There 
was no difference between APS and No-APS individuals in the frequency of reported antipsychotic 
use. However, those with APS reported using psychiatric medication significantly more than those 
without APS (68% vs. 39% respectively). 21 (19.3%) of the participants received low-dose 
antipsychotics and 10 (9.2%) received low-dose lithium as trial treatment at PACE (after study 
entry). The proportion of individuals receiving trial treatment did not differ between the APS and 
No-APS groups.     
 
3.2 Voxel-based morphometry 
Individuals with APS at follow-up had significantly reduced GMV at baseline compared to those 
without APS at follow-up (Figure 1 and Table 2). Reduced GMV was found in clusters 
encompassing the right middle frontal gyrus, right precuneus/posterior cingulate cortex, and left 
inferior temporal gyrus, inferior orbitofrontal gyrus extending to the temporal pole and 
parahippocampal gyrus, inferior and superior occipital cortex and pre- and postcentral gyrus. A 
secondary analysis covarying for baseline IQ did not appreciably change the results. For the other 
contrast (APS>No-APS), no significant differences were detected.  
 
3.3 Correlations with clinical measures 
Mean GMV was negatively correlated with BPRS positive (rho=-.27, p=.006), SANS (rho=-.31, 
p=.001) and HAM-D (rho=-.28, p=.003) scores, and positively correlated with GAF scores (r=.31, 
p=.001) at follow-up in the combined UHR-NT sample (Figure 2). These correlations were not 
significant when performed in the APS and No-APS groups separately. No relationships were 
detected between mean GMV and HAM-A scores at follow-up. No significant correlations were 
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detected between mean GMV and clinical scores or IQ at baseline. Mean GMV was significantly 
associated with change in GAF score (r=.255, p=.007; follow-up minus baseline).      
 
4. Discussion 
This study examined a group of individuals defined as UHR for psychosis at baseline who did not 
transition to psychosis over a medium to long-term follow-up period (mean of 7 years). We 
evaluated baseline MRI scans (i.e. at initial identification as UHR) in this cohort by comparing 
those with APS at the follow-up assessment in comparison to those without such symptoms at 
follow-up. At baseline, both groups were similar in their clinical and demographic characteristics, 
including no differences in APS. At follow-up, the two groups differed significantly on measures of 
positive and negative symptoms, as well as in functioning. Thus, those with attenuated symptoms at 
follow-up had ongoing symptoms and functional disability, despite not meeting criteria for full-
threshold psychosis. 
 
We found that individuals with APS at follow-up had significantly reduced baseline GMV 
compared to those without APS at follow-up. Regions with reduced GMV included the right middle 
frontal (dorsolateral prefrontal cortex) and precuneus/posterior cingulate regions, and left temporal, 
orbital and pre- and postcentral gyri. Reduced volume was also associated with more severe 
positive, negative and depressive symptoms and lower functioning at follow-up. These associations 
were not found in the APS and No-APS groups separately, neither at baseline, suggesting that the 
associations between GMV and later outcome were driven by group membership. Thus, while the 
UHR-NT subgroups did not differ in their clinical characteristics at baseline, differences in GMV 
were discernible at this early stage and these differences were associated with APS and measures of 
psychopathology at follow-up.  
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The regions showing reduced GMV in the APS group are similar to those reported as reduced in 
UHR-T. Reduced volumes or thickness have been demonstrated in UHR-T most consistently across 
temporo-parietal, prefrontal and limbic regions, but also the cerebellum, in cross-sectional 
(Borgwardt et al., 2007; Koutsouleris et al., 2009; Mechelli et al., 2011; Pantelis et al., 2003) and 
longitudinal (Borgwardt et al., 2008; Cannon et al., 2015; Dazzan et al., 2012; Job et al., 2005; 
McIntosh et al., 2011; Pantelis et al., 2003; Ziermans et al., 2012) studies. Our findings in APS are 
largely consistent with the above findings in UHR-T samples. What is novel with the current study 
however is that we have focused on a different aspect of long-term outcome, rather than transition 
as the primary outcome of interest. Thus, our findings suggest that reduced GMV in select frontal, 
temporal and posterior regions at baseline are associated with not only later transition to psychosis 
but to the presence of attenuated psychotic symptoms in a population of UHR individuals who did 
not transition to psychosis after 2-12 years.      
 
At the time of scanning the APS and No-APS groups were clinically indistinguishable. There are 
several interpretations for the volumetric differences detected between them and the associations 
with clinical measures of psychopathology. First, the volumetric reductions may be neurobiological 
markers of an increased risk to psychosis. Thus, an APS outcome in non-transitioned individuals 
might reflect a continuing risk for transition to psychosis, with reduced GMV at baseline 
representing a potential marker for the eventual development of a psychotic disorder. Nevertheless, 
this is unlikely given that the highest risk for transition was found to be within the first 2 years after 
identification as UHR in this sample (Nelson et al., 2013) and the mean follow-up period of the 
APS group in our study was 7.4 years. Second, the volumetric reductions might indeed confer 
increased risk for psychotic disorders, but conventional means for defining psychosis onset are 
ineffective at detecting this risk. Since the threshold for transition from attenuated to frank 
psychotic disorder is arbitrary (Lin et al., 2012; Yung et al., 2010), this currently accepted threshold 
may not be optimal for identifying neurobiological changes associated with psychosis or the 
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schizophrenia spectrum. In the current and wider sample of this cohort (Lin et al., 2015; Lin et al., 
2011), many people who never transition continue to experience functional impairment, negative, 
depressive and attenuated psychotic symptoms years after identification as UHR. It is therefore 
conceivable that this clinical presentation represents „soft‟ or „simple‟ schizophrenia within the 
schizophrenia spectrum, despite the absence of development of full-threshold psychosis. Our 
findings showing reduced GMV at baseline in APS and associations with measures of poor 
outcome supports this view and raises the possibility that brain morphological alterations may occur 
at lower intensity/frequency of positive symptoms. Finally, the baseline volumetric differences may 
represent a neurobiological risk marker for later psychopathology/poor prognosis, rather than later 
presence of psychotic symptoms (threshold or subthreshold) per se. In this context, presence of APS 
at follow-up may reflect “clinical noise” associated with poor prognosis or non-psychotic clinical 
conditions. As above, the associations found between baseline GMV and psychopathology supports 
this view. Although these associations were confounded by group status, it is conceivable that 
individuals grouped on the basis of psychopathology such as negative and depressive symptoms 
would show similar volumetric differences. Despite the GMV differences between APS and No-
APS remaining unclear, these findings have implications for the identification of vulnerability 
markers of psychosis and other outcomes and emphasise the need for future studies to include 
endpoints other than the traditional approach to defining psychosis onset (Lin et al., 2012).    
  
When viewed from the perspective of the No-APS group, our findings suggest that greater GMV at 
baseline is predictive of better outcome and that regional volume confers neurobiological resilience 
in the long-term (for discussion see Pantelis and Bartholomeusz, 2014). Importantly, the group with 
APS at follow-up had also not made the transition to psychosis. Thus, while they may remain 
chronically at high-risk, this lack of transition suggests that other protective factors may be at play.  
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An important question our data raises is whether changes in GMV are associated with changes in 
symptoms and function over time. As described above, longitudinal imaging studies have identified 
brain changes in UHR-T (for review see Bois et al., 2015), but not in UHR-NT (Borgwardt et al., 
2008; McIntosh et al., 2011) individuals. The volumetric differences at baseline may also represent 
a neurobiological process in those with ongoing psychotic features (threshold or subthreshold), 
while the opposite may occur in those without ongoing symptoms. This assertion is supported by a 
recent longitudinal imaging study in UHR-NT individuals (Katagiri et al., 2015), where a relative 
„normalization‟ of white matter integrity correlated with improved clinical outcome. Although we 
found a significant correlation between baseline GMV and change in functioning, it is not known 
whether there were corresponding changes in GMV. Longitudinal studies examining differences in 
trajectories between the APS and No-APS groups would help elucidate whether there is on-going 
neuroprogression or normalization with time associated with different clinical outcomes.  
 
The main strengths of this study are the novel outcome measure (with/without APS) in those who 
did not transition to psychosis and the long follow-up period. The greatest limitation is the variable 
length of the follow-up period and the different field strength of the scanners (1.5 and 3T), although 
these variables were near identical between the APS and No-APS groups and field strength was 
additionally used as a covariate in the between-group analysis.  
 
This study found that differences in regional GMV were discernible at an early stage of UHR and 
may be specific to individuals who continue to have attenuated psychotic symptoms at follow-up. 
Our findings suggest that lower GMV at baseline may confer neurobiological risk for later APS 
and/or increased psychopathology while the absence of these structural abnormalities might be 
protective. Comparison of GMV in the non-transition APS and No-APS groups with a healthy 
control and transitioned (UHR-T) group, along with longitudinal assessment, will help elucidate the 
significance of these findings.   
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Figure Legends 
 
Figure 1. Voxel-based morphometric differences of grey matter volume between APS and No-
APS UHR-NT groups  
A). Areas showing reduced grey matter volume at baseline in non-transitioned UHR individuals 
with APS at follow-up compared to individuals without APS at follow-up (contrast No-APS>APS). 
Clusters resided in the frontal, temporal and posterior regions. T-values at each voxel are provided 
by the scale bar. MNI coordinates are shown on the top of each slice for the y-axis, x-axis and z-
axis, respectively. B). Plot of the mean grey matter volume in the significant clusters in the APS 
and No-APS groups. **** p<.0001. 
 
Figure 2. Relationships between grey matter volume and clinical variables at follow-up in 
UHR-NT 
Scatterplots illustrating the significant correlations between mean grey matter volume in the 
significant cluster in the group comparison with clinical score at follow-up. Reduced grey matter 
volume was associated with increased positive, negative and depressive symptoms and decreased 
functioning at follow-up. Blue squares represent APS individuals and red circles represent No-APS 
individuals. *p<.05, **p<.01.     
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Table and Figures 
Table 1 
Demographic and clinical characteristics of study participants  
Data are expressed as Mean ± SD 
a
Mann-Whitney U standardized test statistic 
BPRS; Brief Psychiatric Rating Scale, SANS; Scale for the Assessment of Negative Symptoms, GAF; Global 
Assessment of Functioning, APS; Attenuated Psychotic Symptoms, BLIPS; Brief Limited Intermittent Psychotic 
Symptoms 
 
 
 No-APS (79) APS (30) t/2 p-value 
Age at baseline (years) 19.80 ± 3.47 19.93 ± 3.44 0.18 .855 
Sex (M/F) 40/39 15/15 .003 .953 
% Scanner Field Strength (1.5T/3T) 51.9/48.1 46.7/53.3 .238 .626 
Time to follow-up (years)  7.61 ± 2.89 7.35 ± 3.16 -0.63
a
 .528 
% Handedness (R/L) 86.5/13.5 82.1/17.9 0.31 .755 
IQ at baseline 103.3 ± 12.1 93.5 ± 15.7 3.39 .001 
Intracranial volume 1411 ± 154 1381 ± 148 .923 .358 
Use of antidepressants at baseline 16.1% 5.0% 1.58 .209 
Use of antipsychotics during follow-up 
period  
2.9% 10.3% 2.40 .148 
Use of any psychiatric medication during 
follow-up period 
38.6% 67.9% 6.89 .013 
Trial treatment with antipsychotics 19% 20% 0.014 .905 
Trial treatment with lithium 8.9% 10% 0.34 .854 
BPRS psychotic subscale at baseline 8.77 ± 2.67 9.59 ± 2.81 1.39 .168 
SANS total at baseline 17.67 ± 11.48 18.55 ± 11.66 0.617
a
 .537 
GAF score at baseline 61.25 ± 11.65 60.33 ± 9.90 0.38 .703 
Intake criteria – APS 58.2% 46.7% 1.17 .291 
Intake criteria – BLIPS 3.8% 13.3% 3.29 .089 
Intake criteria – vulnerability 20.3% 20.0% .001 .977 
Intake criteria – APS and vulnerability 11.4% 13.3% .078 .780 
Intake criteria – APS and BLIPS 3.8% 3.3% .013 .908 
Intake criteria – BLIPS and vulnerability 1.3% 0% .383 .536 
Intake criteria – all three 1.3% 3.3% .516 .473 
BPRS psychotic subscale at follow-up 5.18 ± 1.88 7.20 ± 2.87 3.68
a
 <.001 
SANS total at follow-up 5.60 ± 8.26 15.13 ± 15.24 4.157
a
 <.001 
Hamilton Anxiety Total at follow-up 5.77 ± 5.45 10.90 ± 8.97 3.032
a
 .002 
Hamilton Depression Total 4.97 ± 5.12 12.10 ± 10.03 4.072
a
 <.0001 
GAF score at follow-up 72.67 ± 12.13 59.77 ± 10.16 5.176 <.0001 
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Table 2 
Brain regions demonstrating reduced grey matter volume in APS when compared to No-APS (No-APS>APS), cluster-corrected p-value (p <0.05) 
Anatomical location of 
peak t-value 
Hemisphere Cluster extensions 
 
Max t value MNI coordinates of peak t-value 
Cluster 
size  
Precuneus cortex Right Posterior cingulate gyrus  t=3.65 x=15, y=-45, z=42 1624 
Amygdala Left 
Temporal pole, frontal orbital 
cortex, parahippocampal gyrus 
 
t=3.51 x=-24, y=2, z=-21 949 
Middle frontal gyrus Right   t=4.13 x=40, y=21, z=46 927 
Inferior temporal gyrus Left 
Temporal fusiform cortex, 
posterior and anterior division 
 
t=4.44 x=-46, y=-15, z=-41 761 
Precentral gyrus Left Middle frontal gyrus 
 
t=3.46 x=-36, y=2, z=54 751 
 20 
 
Figure 1. Voxel-based morphometric differences of grey matter volume between APS and No-APS 
UHR-NT groups  
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Figure 2. Relationships between grey matter volume and clinical variables at follow-up in UHR-
NT 
 
 1 
 
 
 
 
Baseline grey matter volume of non-transitioned “ultra high risk” for psychosis individuals with and 
without attenuated psychotic symptoms at long-term follow-up 
 
 
 
Vanessa L. Cropley
1,2
, Ashleigh Lin
5
, Barnaby Nelson
3
,
 
Renate LEP Reniers
4
,
 
Alison R. Yung
6
, 
Cali F. Bartholomeusz
1,2
,
 
Paul Klauser
1,7
, Dennis Velakoulis
1,2
, Patrick McGorry
3
, Stephen J. 
Wood
1,4†
,
 
Christos Pantelis
1,2†
 
  
 
 
1. Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and 
Melbourne Health, Carlton South, Victoria 3053, Australia 
2. Department of Psychiatry, The University of Melbourne, Parkville, Victoria 3052, Australia 
3. Orygen, The National Centre of Excellence in Youth Mental Health, The University of 
Melbourne and Melbourne Health, Parkville, Victoria 3052, Australia 
4. School of Psychology  University of Birmingham, Edgbaston,   Birmingham B15 2TT,   United 
Kingdom 
5. Telethon Kids Institute, The University of Western Australia, Perth, Western Australia 6008, 
Australia 
6. Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester M13 
9PL, United Kingdom 
7. Monash Clinical and Imaging Neuroscience, Monash University, Clayton, Victoria, Australia  
 
 
For correspondence or reprints contact 
Dr Vanessa Cropley, Postdoctoral Research Fellow 
Melbourne Neuropsychiatry Centre, The University of Melbourne 
National Neuroscience Facility, Level 2-3 Alan Gilbert Building 
161 Barry Street, Carlton South VIC 3053 Australia;  
Ph: +61 3 8344 1878, Fax: +61 3 9348 0469  
Email vcropley@unimelb.edu.au 
 
 
Footnote: † These authors contributed equally to this work. 
 
Running Title: Structural imaging in UHR-NP with and without APS 
 
 
*Manuscript - track changes
Click here to view linked References
 2 
Abstract 
Introduction: Two thirds of individuals identified as ultra-high risk (UHR) for psychosis do not 
transition to psychosis over the medium to long-term (non-transition; UHR-NT). Nevertheless, 
many of these individuals, but can have persistent attenuated psychotic symptoms (APS). The 
current study examined whether there were differences in Few studies have examined the biological 
correlates of persistent APS in such individuals. We evaluated baseline grey matter volume (i.e. at 
initial identification as UHR) in a UHR-NT cohort individuals whom had by comparing those with 
APS compared to those without to those without such APSsymptoms (No-APS) assessed at 
medium to long-term follow-up. 
Methods: Participants were help-seeking individuals who were identified as being at UHR for 
psychosis between 2 and 12 years previously (mean=7.5). The sample consisted of 109 participants 
who underwent a Magnetic Resonance Imaging scan at baseline and who had not been observed to 
develop aed psychotic disorder oversis the at follow-up period (UHR-NT). Using voxel-based 
morphometry, baseline grey matter volume (GMV) was compared between participants with 
(N=30) and without (N=79) APS at follow-up.  
Results: At baseline, the APS and No-APS groups were clinically indistinguishable. At follow-up, 
the APS group had significantly worse symptoms and impaired functioning. Individuals with APS 
had reduced baseline GMV in frontal, temporal, posterior and cingulate regions compared to those 
without APS at follow-up. Reduced GMVvolumes wasere associated with more severe positive, 
negative and depressive symptoms and lower global functioning in the combined UHR-NT cohort 
across the entire cohort. These associations were independent of later APS outcome.    
Discussion: This study found that dDifferences in regional GMV are discernible at an early stage of 
UHR and may be specific to individuals who have APS and psychopathology at follow-up. Our 
findings suggest that lower GMV at baseline may confer neurobiological risk for later APS and/or 
increased psychopathology while the absence of these structural abnormalities might be protective.  
 
 3 
Keywords: ultra-high risk, psychosis, attenuated psychotic symptoms, non-transition, imaging, 
grey matter volume  
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1. Introduction 
Previous A large body of research hashas evaluated examined the clinical and 
biologicalneuroanatomical characteristics of clinical help-seeking samples identified as being at 
ultra high-risk (UHR) for psychosis. Both Crcross-sectional and longitudinal studies have primarily 
typically focused on identifying differences between individuals with clinical UHR in comparison 
to healthy controls, as well as individuals categorized either as having transitioned (UHR-T) or not 
transitioned (UHR-NT) to psychosis, as well as in comparison to healthy controls in order to 
identify vulnerability predictors for transition to psychotic illness. RSuch research employing 
structural magnetic resonance imaging (MRI) has reported subtle but widespread neuroanatomical 
structural brain abnormalities in temporo-parietal, prefrontal and limbic regions in UHR, with 
evidence for more pronounced abnormalities in UHR-T  in select frontal, temporal and limbic 
structures (for reviews see Bois et al., 2015; Fusar-Poli et al., 2011; Smieskova et al., 2010). , 
suggesting that these regions may be associated with progression to a psychotic illness. However, 
about two-thirds of help-seeking individuals identified as at risk for developing psychosis do not 
transition to frank psychotic disorder over the medium term (Fusar-Poli et al., 2012). This suggests 
that neuroanatomical alterations in UHR may represent markers other than, or in addition to, 
vulnerability to psychosis, such as outcomes related to non-transition or other non-psychotic 
disorders.  and recent UHR cohorts have shown decreasing transition rates (Nelson et al., 2013; 
Yung et al., 2007), suggesting that the proportion of non-transitioned individuals may be even 
higher. Despite the large proportion of UHR individuals who do not develop psychosis there is little 
research examining the clinical and biological correlates of this cohort followed over the long-term.  
 
There is a paucity of imaging studies in UHR that have specifically assessed the morphological 
characteristics of individuals who did not develop psychosis. Of studies that compared UHR-NT 
individuals to controls, increases (Fornito et al., 2008), decreases (Garner et al., 2005; Phillips et al., 
2002) and no change (McIntosh et al., 2011; Takahashi et al., 2009; Ziermans et al., 2012) in brain 
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structure have been identified in UHR-NT. Even fewer studies have examined neuroimaging 
indices in relation to clinical outcomes of UHR-NT. To our knowledge, only one brain structural 
study has defined subgroups of UHR-NT according to their long-term clinical outcome; those who 
remained „well‟ (no symptoms) and those who reported one or more psychotic symptoms 
throughout the follow-up period (McIntosh et al., 2011). Although no differences in brain structure 
(either at baseline or over time) were detected between the two UHR-NT subgroups, this study 
raises the possibility that other outcomes of the UHR-NT group might be associated with discrete 
neurobiological changes. In addition, as this study consisted of relatives who were at risk for 
schizophrenia (genetic at-risk paradigm) it is possible that individuals with an elevated risk for 
psychosis based on clinical or help-seeking factors might show a different neuroanatomical profile 
(see Nenadic et al., 2015). 
 
 
 
In UHR samples, which consist of individuals who will and will not transition to psychosis, brain 
volume reductions have been identified in a diffuse network including temporo-parietal, bilateral 
prefrontal and limbic cortex (Fusar-Poli et al., 2011). These findings are typically viewed from the 
prism of psychosis, with reductions representing widespread neuroanatomical correlates of an 
increased vulnerability to psychosis. However, given thatRecent studies have demonstrated that 
UHR-NT individuals represent a heterogeneous grouphave a wide range of outcomes with respect 
to symptomatic, functional and non-psychotic disability (Schlosser et al., 2012). At follow-up, 
many individuals present with, neuroanatomical alterations in UHR may also represent markers of 
resilience or outcomes related to non-transition or other disorders, rather than vulnerability to 
psychosis by itself. Nearly half of UHR studies have not provided characteristics of participants 
who did not develop psychosis (Simon et al., 2011), demonstrating that there is little understanding 
of the profile of these individuals. As such, it has been recommended that research studies expand 
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the range of outcomes to be assessed. These include the persistence or remission of attenuated 
symptoms, functional disability, negative symptoms, non-psychotic disorders as well as psychosis 
(Lin et al., 2012; Lin et al., 2013; Yung et al., 2012).  
  
Studies have recently begun to examine the outcomes for individuals who have not developed a 
psychotic disorder at follow-up (i.e. UHR-NT). In addition to presenting with significant non-
psychotic mental health problems, poor psychosocial functioning and negative symptoms (e.g. 
Addington et al., 2011; Lin et al., 2011; Salokangas et al., 2013). A, a proportion (23-50%) of 
UHR-NT individuals  also experience attenuated psychotic symptoms (APS) at follow-up 
(Addington et al., 2011; Haroun et al., 2006; Lemos-Giraldez et al., 2009; Simon and Umbricht, 
2010; Velthorst et al., 2011; Ziermans et al., 2011), which often co-occur with functional 
impairment and comorbidity. . The presence of APS in UHR-NT individuals provides the 
opportunity to assess the impact of subthreshold intensity or frequency of psychotic symptoms on 
biological indices. This is highly relevant given recent discussions concerning the arbitrary nature 
of the cut-off for psychosis that may not be optimal for measuring associated functional and 
neurobiological changes (see Lin et al., 2012). As As the UHR literature has primarily examined 
neurobiological correlates of threshold psychotic symptoms (i.e. symptoms exceeding the threshold 
for frank psychotic disorder), the neurobiological associations of attenuated (subthreshold) 
psychotic symptoms remain unknown. Examination of brain structural indices associated with 
different outcomes of APS in those who do not transition is important for refining our 
understanding of the biological correlates of the at-risk mental state.  
 
We have recently examined the course and outcomes of UHR individuals who did not develop a 
psychotic disorder over a period of 2 to 14 years (the PACE 400 sample) (Lin et al., 2015). This 
work identified that 28% of individuals reported APS at follow-up. The current study aimed to 
assess the brain structural predictors of the APS outcome in this UHR-NTnon-transitioned UHR 
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cohort (UHR-NT). We sought to examine whether there were differences in baseline grey matter 
volume (GMV) in UHR-NT individuals whom had APS compared to those who did not experience 
such symptoms at follow-up (No-APS). Based on structural imaging studies in UHR-T, and given 
the arbitrary nature of the „psychosis threshold‟ (Yung et al., 2010), we predicted that individuals 
with APS at follow-up would have reduced GMV at baseline in prefrontal, temporal and limbic 
regions compared to UHR-NT individuals with out APS at follow-up (No-APS).      
 
2. Methods 
2.1 Participants and design 
PACE is a specialist clinic for young people at UHR for psychosis in Melbourne, Australia. Data 
for the current study was taken from a larger sample of 416 UHR individuals, described previously 
(Lin et al., 2015; Nelson et al., 2013). The current study involves only the UHR-NT individuals 
whom had undergone a structural MRI scan at baseline (N=114). Of these participants, 34 presented 
with current APS at follow-up that were at/above the threshold for UHR (but below the threshold 
for transition) and 80 reported no APS (below UHR threshold; No-APS) at follow-up (see Lin et al., 
2015 for full description of APS in the wider PACE sample). The presence of APS was not 
measured in the interim of the baseline and follow-up assessment. Of this dataset, 5 scans were 
excluded; one for having a different voxel size to the rest of the scans and 4 for having poor 
covariance after preprocessing, leaving a total sample of 109 individuals (30 APS, 79 No-APS at 
follow-up) in the current study.  
 
At baseline, participants were aged 15 to 30 years and met UHR criteria, defined by presenting with 
at least one of: 1) attenuated psychotic symptoms, 2) brief limited intermittent psychotic symptoms, 
and/or 3) trait vulnerability for psychotic illness (schizotypal personality disorder or history of 
psychosis in a first-degree relative) and deterioration in functioning or chronic low functioning (see 
Nelson et al., 2013 for full description of UHR criteria of this cohort). Exclusion criteria for entry to 
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PACE are a previous psychotic episode, organic cause for presentation or past anti-psychotic 
exposure equivalent to a haloperidol dose of >15 mg. Participants with and without APS were 
matched for age and gender. The local Research and Ethics Committee approved the study. All 
participants provided written informed consent.  
 
2.3 Clinical measures 
At Bbaseline, psychopathology was measured using the psychotic subscale of the Brief Psychiatric 
Rating Scale (BPRS) (Overall and Gorham, 1962), Scale of Assessment for Negative Symptoms 
(SANS) (Andreasen, 1981) and The Comprehensive Assessment of At-Risk Mental States 
(CAARMS) (Yung et al., 2005). CAARMS positive subscales were disorders of thought content, 
perceptual abnormalities and conceptual disorganisation. Functioning was assessed with the Global 
Assessment of Functioning (GAF) (Endicott et al., 1976) and current IQ with the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R; Wechsler, 1981) or the Wechsler Abbreviated Scale of 
Intelligence (WASI; Wechsler, 1999) following the procedure outlined in Lin et al., (2011).. 
Younger participants were assessed using the Wechsler Intelligence Scale for Children (WISC-III; 
Wechsler, 1991) as an alternative to the WAIS-R. At follow-up the CAARMS was used to assess 
the presence of APS. Psychopathology was measured using the BPRS, SANS, Hamilton Anxiety 
Rating Scale (HAM-A) (Hamilton, 1959) and Hamilton Depression Rating Scale (HAM-D) 
(Hamilton, 1960) and. fFunctioning was assessed with the GAF.  
 
2.4 MRI acquisition 
50.5%52% of the T1-weighted MRI scans were acquired on a 1.5T GE Signa MR scanner with the 
following parameters: 124 slices of 1.5mm thickness, TR=1.43s, TE=3.3ms, flip angle 30º, matrix 
256x256, FOV 24cm. The remaining 49.547% of MRI scans were acquired on a 3T GE LX 
Horizon Scanner: 124 slices of 2mm thickness, TR=3.6s, TE=9ms, flip angle 30º, matrix 410x410, 
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FOV 20cm. The APS and No-APS groups were matched on the proportion undergoing 1.5T versus 
3T. 
 
2.5 Voxel-based morphometry 
Whole-brain voxelwise analysis of baseline GMV was conducted using optimized voxel-based 
morphometry (VBM8), as implemented in statistical parametric mapping (SPM8) software 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) running in Matlab R2014b 
http://www.mathworks.com.au/products/matlab/). Briefly, T1 images were normalized to a template 
space and segmented into grey matter, white matter and cerebrospinal fluid. Native-space grey 
matter segments were then spatially aligned to a high-dimensional Diffeomorphic Anatomical 
Registration Through Exponentiated Lie Algebra (DARTEL) template and normalized to MNI 
space. Grey matter voxels were multiplied by the non-linear components only (modulated 
normalized – non-linear only) to provide a measure of the absolute amount of tissue corrected for 
individual brain sizes. Data quality and homogeneity of the images were checked. Images of four 
participants were excluded from the original dataset due to the covariance being more than two 
standard deviations removed from the mean. Prior to statistical analysis, images were smoothed 
with an 8mm full-width-half-maximum Gaussian kernel.    
 
2.6 Statistical analysis 
The General Linear Model (GLM) was performed to test for group differences in baseline GMV at 
each voxel. An independent t-test with age at baseline, sex and field strength of the scanner as 
nuisance factors was defined to test for volumetric differences between the APS and No-APS 
groups. Group differences were corrected for statistical type I error with a cluster-based procedure 
(Friston et al., 1994) using the 3dClustSim tool implemented in AFNI 
(http://afni.nimh.nih.gov/pub/dist/doc/program_help/3dClustSim.html). A voxel-wise threshold was 
set to 0.01 to compromise between sensitivity to spatially extended versus focal and intense 
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differences. Cluster size threshold (i.e. k values) was corrected for non-stationarity (Hayasaka et al., 
2004) with the VBM8 toolbox (http://dbm.neuro.uni-jena.de/467/).  
 
Statistical analyses of demographic and clinical variables were performed using the Statistical 
Package for Social Sciences (SPSS, v21.0). Differences in these variables between groups were 
analysed with independent t-tests or Pearson‟s 2 statistics for continuous and categorical variables, 
respectively. The Mann-Whitney U Test was performed for non-parametric variables. Correlations 
were analysed between the mean GMV extracted from the significant cluster detected in the group 
comparison and clinical variables at follow-up (BPRS, SANS, GAF, HAM-A, HAM-D) using 
Pearson‟s correlation coefficient with bootstrapping (5000 samples) or to control for skewed 
distributions.Spearman‟s correlation coefficient for non-parametric variables. Correlations were 
performed in the whole (combined) sample and in each group (APS and No-APS) separately. 
Correlations between mean GMV and clinical variables at baseline, and with change scores (follow-
up minus baseline score), were explored. P-values <0.05 was considered statistically significant.  
 
3. Results 
3.1 Demographics and clinical characteristics of study sample 
Demographic and clinical characteristics of the APS and No-APS groups are presented in Table 1. 
In this sample, follow-up was conducted between 2 and 12 years after baseline (M=7.5; SD=3.0; 
median=6.9). The APS and No-APS groups were well matched in age at baseline, sex, field 
strength of scanner, time to follow-up and in the UHR membership criteria at intake. At baseline, 
the APS and No-APS groups showed no differences in positive and negative symptoms and 
functioning. However the APS group had a significantly lower IQ than the No-APS group. At 
follow-up, the APS group had significantly higher symptoms (positive, negative, anxiety and 
depression) and lower functioning. Antipsychotic and antidepressant use at baseline (i.e. at time of 
scanning) was documented for 70% of the sample. Of these participants, none reported taking 
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antipsychotics and 10 (13.2%) reported using antidepressants. Antipsychotic and psychiatric 
medication use for the entire follow-up period (i.e. after baseline) was documented for 90% of the 
sample. Of these participants, 5 (5.1%) reported using antipsychotic medication and 46 (47%) 
reported using any psychiatric medication “some or all of the time” in the follow-up period. There 
was no difference between APS and No-APS individuals in the frequency of reported antipsychotic 
use. However, those with APS reported using psychiatric medication significantly more than those 
without APS (68% vs. 39% respectively). 21 (19.3%) of the participants received low-dose 
antipsychotics and 10 (9.2%) received low-dose lithium as trial treatment at PACE (after study 
entry). The proportion of individuals receiving trial treatment did not differ between the APS and 
No-APS groups.     
 
3.2 Voxel-based morphometry 
Individuals with APS at follow-up had significantly reduced GMV at baseline compared to those 
without APS at follow-up (Figure 1 and Table 2). Reduced GMV was found in clusters 
encompassing the right middle frontal gyrus, right precuneus/posterior cingulate cortex, and left 
inferior temporal gyrus, inferior orbitofrontal gyrus extending to the temporal pole and 
parahippocampal gyrus, inferior and superior occipital cortex and pre- and postcentral gyrus. A 
secondary analysis covarying for baseline IQ did not appreciably change the results. For the other 
contrast (APS>No-APS), no significant differences were detected.  
 
3.3 Correlations with clinical measures 
Mean GMV was negatively correlated with BPRS positive (rho=-.273, p=.00618), SANS (rho=-
.313, p=.001) and HAM-D (rho=-.287, p=.0034) scores, and positively correlated with GAF scores 
(r=.31, p=.001) at follow-up in the combined UHR-NT sample (Figure 2). These correlations were 
not significant when performed in the APS and No-APS groups separately.When performed 
separately, only SANS showed a significant correlation with GMV in the No-APS group, whilst no 
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variables were significantly associated with GMV in APS. No relationships were detected between 
mean GMV and HAM-A scores at follow-up. No significant correlations were detected between 
mean GMV and clinical scores or IQ at baseline. Mean GMV was significantly associated with 
change in SANS (r=-.19, p=.048) and GAF score (r=.255, p=.007;) scores (follow-up minus 
baseline).      
 
4. Discussion 
This study examined a group of individuals defined as UHR for psychosis at baseline who did not 
transition to psychosis over a medium to long-term follow-up period (mean of 7 years). We 
evaluated baseline MRI scans (i.e. at initial identification as UHR) in this cohort by comparing 
those with APS at the follow-up assessment in comparison to those without such symptoms at 
follow-up. At baseline, both groups were similar in their clinical and demographic characteristics, 
including no differences in APS. At follow-up, the two groups differed significantly on measures of 
BPRS positive and SANS negative symptoms, as well as in functioning (GAF). Thus, those with 
attenuated symptoms at follow-up had ongoing symptoms and functional disability, despite not 
meeting criteria for full-threshold psychosis. 
 
We found that individuals with APS at follow-up had significantly reduced baseline GMV 
compared to those without APS at follow-up. Regions with reduced GMV included the right middle 
frontal (dorsolateral prefrontal cortex) and precuneus/posterior cingulate regions, and left temporal, 
orbital and pre- and postcentral gyri. Reduced volume was also associated with more severe 
positive, negative and depressive symptoms and lower functioning at follow-up. These associations 
were not found in the APS and No-APS groups separately, neither at baseline, suggesting that the 
associations between GMV and later outcome were driven by group membership.  Interestingly, 
these correlations were not present at baseline. Thus, while the UHR-NT subgroups did not differ in 
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their clinical characteristics at baseline, differences in GMV were discernible at this early stage and 
these differences were associated with APS and measures of psychopathology at follow-up.  
 
The regions showing reduced GMV in the APS group are similar to those reported as reduced in 
UHR individuals who later develop psychosis (UHR-T). Reduced volumes or thickness have been 
demonstrated in UHR-T most consistently across temporo-parietal, prefrontal and limbic regions, 
but also the cerebellum, in cross-sectional We were the first to report volumetric reductions, namely 
in the right hippocampal, parahippocampal and cingulate cortex, lateral temporal and inferior 
frontal cortex, in individuals who transitioned to psychosis (UHR-T) compared to those that didn‟t 
(Borgwardt et al., 2007; Koutsouleris et al., 2009; Mechelli et al., 2011; Pantelis et al., 2003).Other 
regions reported as reduced in UHR-T individuals include the superior temporal gyrus and insula 
prefrontal and orbitofrontal cortex  and left parahippocampus and longitudinal. Longitudinal studies 
have reported progressive reductions in UHR-T compared to UHR-NT individuals in regions 
including the medial and inferior temporal cortex, orbitofrontal, superior frontal, medial and 
superior parietal cortex, cingulate cortex and cerebellum (Borgwardt et al., 2008; Cannon et al., 
2015; Dazzan et al., 2012; Job et al., 2005; McIntosh et al., 2011; Pantelis et al., 2003; Ziermans et 
al., 2012) studies. With the exception of the cerebellum and insula, Oour findings in the APS group 
are largely consistent with the above findings in UHR-T samples. What is novel with the current 
study however is that we have focused on a different aspect of long-term outcome, rather than 
transition as the primary outcome of interest. Thus, our findings suggest that reduced GMV in select 
frontal, temporal and posterior regions at baseline are associated with not only later transition to 
psychosis but to the presence of attenuated psychotic symptoms in a population of UHR individuals 
who did not transition to psychosis after 2-12 years.      
 
At the time of scanning the APS and No-APS groups were clinically indistinguishable. There are 
several interpretations for the volumetric differences detected between them and the associations 
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with clinical measures of psychopathology. First, the volumetric reductions may be neurobiological 
markers of an increased risk to psychosis. Thus, an APS outcome in non-transitioned individuals 
might reflect a continuing risk for transition to psychosis, with reduced GMV at baseline 
representing a potential marker for the eventual development of a psychotic disorder. Nevertheless, 
this is unlikely given that the highest risk for transition was found to be within the first 2 years after 
identification as UHR in this sample (Nelson et al., 2013) and the mean follow-up period of the 
APS group in our study was 7.4 years. Second, the volumetric reductions might indeed confer 
increased risk for psychotic disorders, but conventional means for defining psychosis onset are 
ineffective at detecting this risk. Since the threshold for transition from attenuated to frank 
psychotic disorder is arbitrary (Lin et al., 2012; Yung et al., 2010), this currently accepted threshold 
may not be optimal for identifying neurobiological changes associated with psychosis or the 
schizophrenia spectrum. In the current and wider sample of this cohort (Lin et al., 2015; Lin et al., 
2011), many people who never transition continue to experience functional impairment, negative, 
depressive and attenuated psychotic symptoms years after identification as UHR. It is therefore 
conceivable that this clinical presentation represents „soft‟ or „simple‟ schizophrenia within the 
schizophrenia spectrum, despite the absence of development of full-threshold psychosis. Our 
findings showing reduced GMV at baseline in APS and associations with measures of poor 
outcome supports this view and raises the possibility that brain morphological alterations may occur 
at lower intensity/frequency of positive symptoms. Finally, the baseline volumetric differences may 
represent a neurobiological risk marker for later psychopathology/poor prognosis, rather than later 
presence of psychotic symptoms (threshold or subthreshold) per se. In this context, presence of APS 
at follow-up may reflect “clinical noise” associated with poor prognosis or non-psychotic clinical 
conditions. As above, the associations found between baseline GMV and psychopathology supports 
this view. Although these associations were confounded by group status, it is conceivable that 
individuals grouped on the basis of psychopathology such as negative and depressive symptoms 
would show similar volumetric differences. Although our understanding ofDespite the GMV 
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differences between the APS and No-APS groups remaining unclear, theseour findings have 
implications for the identification of vulnerability markers of psychosis and other outcomes and 
emphasise the need for future studies to include endpoints other than the traditional approach to 
defining psychosis onset (Lin et al., 2012).    
  
When viewed from the perspective of the No-APS group, our findings suggest that greater GMV at 
baseline is predictive of better outcome and that regional volume confers neurobiological resilience 
in the long-term (for discussion see Pantelis and Bartholomeusz, 2014). Importantly, the group with 
APS at follow-up had also not made the transition to psychosis. Thus, while they may remain 
chronically at high-risk, this lack of transition suggests that other protective factors may be at play.  
 
An important question our data raises is whether changes in GMV are associated with changes in 
symptoms and function over time. As described above, longitudinal imaging studies in UHR have 
identified brain changes in individuals that transition to psychosisUHR-T (for review see Bois et al., 
2015), but not in those who do not transitionUHR-NT (Borgwardt et al., 2008; McIntosh et al., 
2011) individuals. The volumetric differences at baseline may also represent a neurobiological 
process in those with ongoing psychotic features (threshold or subthreshold), while the opposite 
may occur in those without ongoing symptoms. This assertion is supported by a recent longitudinal 
imaging study in UHR-NT individuals (Katagiri et al., 2015)who did not transition to psychosis , 
where a relative „normalization‟ of white matter integrity correlated with improved clinical 
outcome. Although we found a significant correlation between baseline GMV and change in 
negative symptoms and functioning, it is not known whether there were corresponding changes in 
GMV. Longitudinal studies examining differences in trajectories between the APS and No-APS 
groups would help elucidate whether there is on-going neuroprogression or normalization with time 
associated with different clinical outcomes.  
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The main strengths of this study are the novel outcome measure (with/without APS) in those who 
did not transition to psychosis and the long follow-up period. The greatest limitation is the variable 
length of the follow-up period and the different field strength of the scanners (1.5 and 3T), although 
these variables were near identical between the APS and No-APS groups and field strength was 
additionally used as a covariate in the between-group analysis.  
 
This study found that differences in regional GMV were discernible at an early stage of UHR and 
may be specific to individuals who continue to have attenuated psychotic symptoms at follow-up. 
Our findings suggest that lower GMV at baseline may confer neurobiological risk for later APS 
and/or increased psychopathology while the absence of these structural abnormalities might be 
protective. Comparison of GMV in the non-transition APS and No-APS groups with a healthy 
control and transitioned (UHR-T) group, along with longitudinal assessment, will help elucidate the 
significance of these findings.   
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Figure Legends 
 
Figure 1. Voxel-based morphometric differences of grey matter volume between APS and No-
APS UHR-NT groups  
A). Areas showing reduced grey matter volume at baseline in non-transitioned UHR individuals 
with APS at follow-up compared to individuals without APS at follow-up (contrast No-APS>APS). 
Clusters resided in the frontal, temporal and posterior regions. T-values at each voxel are provided 
by the scale bar. MNI coordinates are shown on the top of each slice for the y-axis, x-axis and z-
axis, respectively. B). Plot of the mean grey matter volume in the significant clusters in the APS 
and No-APS groups. **** p<.0001. 
 
Figure 2. Relationships between grey matter volume and clinical variables at follow-up in 
UHR-NT 
Scatterplots illustrating the significant correlations between mean grey matter volume in the 
significant cluster in the group comparison with clinical score at follow-up. Reduced grey matter 
volume was associated with increased positive, negative and depressive symptoms and decreased 
functioning at follow-up. Blue squares represent APS individuals and red circles represent No-APS 
individuals. *p<.05, **p<.01.     
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Table and Figures 
Table 1 
Demographic and clinical characteristics of study participants  
Data are expressed as Mean ± SD 
a
Mann-Whitney U standardized test statistic 
BPRS; Brief Psychiatric Rating Scale, SANS; Scale for the Assessment of Negative Symptoms, GAF; Global 
Assessment of Functioning, APS; Attenuated Psychotic Symptoms, BLIPS; Brief Limited Intermittent Psychotic 
Symptoms 
 
 
 No-APS (79) APS (30) t/2 p-value 
Age at baseline (years) 19.80 ± 3.47 19.93 ± 3.44 0.18 .855 
Sex (M/F) 40/39 15/15 .003 .953 
% Scanner Field Strength (1.5T/3T) 51.9/48.1 46.7/53.3 .238 .626 
Time to follow-up (years)  7.61 ± 2.89 7.35 ± 3.16 -0.63
a
 .528 
% Handedness (R/L) 86.5/13.5 82.1/17.9 0.31 .755 
IQ at baseline 103.3 ± 12.1 93.5 ± 15.7 3.39 .001 
Intracranial volume 1411 ± 154 1381 ± 148 .923 .358 
Use of antidepressants at baseline 16.1% 5.0% 1.58 .209 
Use of antipsychotics during follow-up 
period  
2.9% 10.3% 2.40 .148 
Use of any psychiatric medication during 
follow-up period 
38.6% 67.9% 6.89 .013 
Trial treatment with antipsychotics 19% 20% 0.014 .905 
Trial treatment with lithium 8.9% 10% 0.34 .854 
BPRS psychotic subscale at baseline 8.77 ± 2.67 9.59 ± 2.81 1.39 .168 
SANS total at baseline 17.67 ± 11.48 18.55 ± 11.66 0.617
a
 .537 
GAF score at baseline 61.25 ± 11.65 60.33 ± 9.90 0.38 .703 
Intake criteria – APS 58.2% 46.7% 1.17 .291 
Intake criteria – BLIPS 3.8% 13.3% 3.29 .089 
Intake criteria – vulnerability 20.3% 20.0% .001 .977 
Intake criteria – APS and vulnerability 11.4% 13.3% .078 .780 
Intake criteria – APS and BLIPS 3.8% 3.3% .013 .908 
Intake criteria – BLIPS and vulnerability 1.3% 0% .383 .536 
Intake criteria – all three 1.3% 3.3% .516 .473 
BPRS psychotic subscale at follow-up 5.18 ± 1.88 7.20 ± 2.87 3.68
a
 <.001 
SANS total at follow-up 5.60 ± 8.26 15.13 ± 15.24 4.157
a
 <.001 
Hamilton Anxiety Total at follow-up 5.77 ± 5.45 10.90 ± 8.97 3.032
a
 .002 
Hamilton Depression Total 4.97 ± 5.12 12.10 ± 10.03 4.072
a
 <.0001 
GAF score at follow-up 72.67 ± 12.13 59.77 ± 10.16 5.176 <.0001 
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Table 2 
Brain regions demonstrating reduced grey matter volume in APS when compared to No-APS (No-APS>APS), cluster-corrected p-value (p <0.05) 
Anatomical location of 
peak t-value 
Hemisphere Cluster extensions 
 
Max t value MNI coordinates of peak t-value 
Cluster 
size  
Precuneus cortex Right Posterior cingulate gyrus  t=3.65 x=15, y=-45, z=42 1624 
Amygdala Left 
Temporal pole, frontal orbital 
cortex, parahippocampal gyrus 
 
t=3.51 x=-24, y=2, z=-21 949 
Middle frontal gyrus Right   t=4.13 x=40, y=21, z=46 927 
Inferior temporal gyrus Left 
Temporal fusiform cortex, 
posterior and anterior division 
 
t=4.44 x=-46, y=-15, z=-41 761 
Precentral gyrus Left Middle frontal gyrus 
 
t=3.46 x=-36, y=2, z=54 751 
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Figure 1. Voxel-based morphometric differences of grey matter volume between APS and No-APS 
UHR-NT groups  
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Figure 2. Relationships between grey matter volume and clinical variables at follow-up in UHR-
NT 
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